

Open access • Posted Content • DOI:10.1101/620047

Long read sequencing reveals a novel class of structural aberrations in cancers: identification and characterization of cancerous local amplifications — Source link


Yoshitaka Sakamoto, Liu Xu, Masahide Seki, Toshiyuki T. Yokoyama ...+11 more authors

Institutions: University of Tokyo, National Cancer Research Institute

Published on: 29 Apr 2019 - bioRxiv (Cold Spring Harbor Laboratory)

Related papers:

- · Genome-Wide Identification of Somatic Aberrations from Paired Normal-Tumor Samples
- Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.
- · Decoding complex patterns of genomic rearrangement in hepatocellular carcinoma
- The genomic landscape of metastatic castration-resistant prostate cancers using whole genome sequencing reveals multiple distinct genotypes with potential clinical impact
- · Interstitial Deletions Generating Fusion Genes.



1	Long read sequencing reveals a novel class of structural aberrations in cancers:					
2	identification and characterization of cancerous local amplifications					
3						
4	Yoshitaka Sakamoto ¹ , Liu Xu ¹ , Masahide Seki ¹ , Toshiyuki T. Yokoyama ¹ , Masahiro					
5	Kasahara ¹ , Yukie Kashima ^{2,3} , Akihiro Ohashi ³ , Yoko Shimada ⁴ , Noriko Motoi ⁵ , Katsuya					
6	Tsuchihara², Susumu Kobayashi³, Takashi Kohno⁴, Yuichi Shiraishi ⁶ , Ayako Suzuki¹,					
7	Yutaka Suzuki ^{1*}					
8						
9	Affiliations					
10	¹ Department of Computational Biology and Medical Sciences, Graduate School of					
11	Frontier Sciences, The University of Tokyo, Chiba, Japan.					
12	² Division of Translational Informatics, Exploratory Oncology Research and Clinical					
13	Trial Center, National Cancer Center, Chiba, Japan.					
14	³ Division of Translational Genomics, Exploratory Oncology Research and Clinical Trial					
15	Center, National Cancer Center, Chiba, Japan.					
16	⁴ Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan.					
17	⁵ Department of Pathology, National Cancer Center Hospital, Tokyo, Japan.					
18	⁶ Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo,					
19	Japan.					
20						
21	*To whom correspondence should be addressed. Yutaka Suzuki; Tel: +81 4 7136 3607;					
22	Fax: +81 4 7136 3607; Email: ysuzuki@hgc.jp.					
23						
24	Email address:					
25	Yoshitaka Sakamoto (sakamoto_yoshitaka_18@stu-cbms.k.u-tokyo.ac.jp)					
26	Liu Xu (xu_liu_18@stu·cbms.k.u·tokyo.ac.jp)					
27	Masahide Seki (mseki@edu.k.u tokyo.ac.jp)					
28	Toshiyuki T. Yokoyama (yokoyama_toshiyuki_17@stu-cbms.k.u-tokyo.ac.jp)					
29	Masahiro Kasahara (mkasa@edu.k.u tokyo.ac.jp)					
30	Yukie Kashima (ykashima@east.ncc.go.jp)					
31	Akihiro Ohashi (aohashi@east.ncc.go.jp)					
32	Yoko Shimada (yoshimad@ncc.go.jp)					
33	Noriko Motoi (nmotoi@ncc.go.jp)					
34	Katsuya Tsuchihara (ktsuchih@east.ncc.go.jp)					
35	Susumu Kobayashi (sukobaya@east.ncc.go.jp)					

36 Takashi Kohno (tkkohno@ncc.go.jp)

- 37 Yuichi Shiraishi (yuishira@ncc.go.jp)
- 38 Ayako Suzuki (asuzuki@edu.k.u tokyo.ac.jp)
- 39 Yutaka Suzuki (ysuzuki@hgc.jp)
- 40
- 41 Keywords:
- 42 Long read sequencing, Lung cancer, Local structural aberrations
- 43
- 44 Running title: Cancerous local copy-number lesions in lung cancers

45 ABSTRACT

46Here we report identification of a new class of local structural aberrations in lung cancers. The whole genome sequencing of cell lines using a long read sequencer, 4748PromethION, demonstrated that typical cancerous mutations, such as point mutations, 49large deletions and gene fusions can be detected also on this platform. Unexpectedly, we 50revealed unique structural aberrations consisting of complex combinations of local duplications, inversions and micro deletions. We further analyzed and found that these 5152mutations also occur in vivo even in key cancer related genes. These mutations may 53elucidate the molecular etiology of patients for whom causative cancerous events and 54therapeutic strategies remain elusive.

55 INTRODUCTION

56Recent cancer sequencing projects, such as the International Cancer Genome 57Consortium (ICGC) and The Cancer Genome Atlas (TCGA), have revealed causative 58mutations in various types of cancers^{1,2}. Among them, lung adenocarcinomas are one of the most well-studied cancers regarding such "cancer driver" mutations³⁻⁶. In lung 5960 cancer patients, more than half of the cases have characteristic point mutations in the 61EGFR and KRAS genes or gene fusions in the ALK, RET and ROS1 genes. These 62mutations are utilized as "biomarkers", providing fundamental information about the 63 most appropriate therapeutic strategy. Patients are separated based on their genomic 64mutation statuses and are matched to the most appropriate treatment⁷⁻¹¹. Despite this general success, approximately 20.30 % of the lung adenocarcinoma patients remain 6566 undiagnosed with respect to their cancerous mutations⁷.

67Current information on the cancer mutations has been mostly obtained by 68 short read sequencing. Short read sequencing data, generally consisting of tens of millions reads of up to 200-300 bases in length¹², are the most powerful in detecting 6970point mutations such as single nucleotide variants (SNVs) and short indels^{5,13}. 71Significant efforts have been made to enable the identification of fusion genes by short 72read sequences¹⁴. However, it is still difficult to detect more complex or larger scale 73structural aberrations, such as chromosome aneuploidy, copy number aberrations and rearrangements solely based on short read sequencing data. There are inherent 7475drawbacks even in the latest bioinformatics pipelines for this purpose, which hampers 76their practical use without careful validation¹⁵.

77Recently developed long read sequencing technologies are changing this 78situation. Several pioneering papers have reported the precise analysis of complicated 79 genomic regions, and large range aberration detection is enabled by the long read 80 sequencing. For example, a single molecule real-time (SMRT) sequencer, PacBio RS, has been utilized to analyze BCR-ABL1 rearranged transcripts and their TKI-resistant 81 mutations in chronic myeloid leukemia (CML)^{16,17}. In Chromophobe Renal Cell 82 Carcinoma (ChRCC), structural alterations in the TERT promoter region have been 83 identified and characterized by PacBio sequencing¹⁸. Very recently, a nanopore-type 8485sequencer, MinION, was first utilized to characterize the pathogenic sequence expansion of intronic repeats in Benign Adult Familial Myoclonic Epilepsy (BAFME)¹⁹. 86 Particularly for cancer applications, we and others have shown that cancer-associated 87 88 structural variants (SVs) could be detected by nanopore sequencing approaches $2^{20,21}$. 89 Additionally, transcriptome sequencing by MinION has been shown to provide a 90 powerful analytical platform, where the complete splicing pattern of a given mRNA can 91 be thoroughly represented by a single read²². Further improvements in MinION
92 sequencing have been achieved by the parallelization of the nanopores in a given flow
93 cell, a platform named PromethION. PromethION can now produce over 100 Gb reads
94 per flow cell.

95In this study, we attempted long read sequencing of whole human cancer genomes using PromethION. We first demonstrate that PromethION sequencing can 9697identify point mutations as well as large structural aberrations and fusion genes 98relatively easily. Moreover, we unexpectedly identified that mutations containing 99 complex combinations of small and middle-sized structural aberrations are quite 100 common, constituting a previously undefined unique class of mutations. Hereafter, we 101 will call those mutations Cancerous Local Copy number Lesions (CLCLs). These CLCLs 102resided even within the key cancer genes or drug target genes, such as the STK11, NF1 103 SMARCA4 and PTEN genes. Additionally, taking advantage of long read sequencing, 104 we characterized the full-length transcript structures by full-length cDNA sequencing of 105the transcriptome.

106 We initially used lung cancer cell lines for which we had previously collected 107 detailed information on multi-omics features, such as whole-genome sequencing, 108 RNA-seq, and ChIP-seq of Illumina reads²³. Then, we used clinical samples to 109 demonstrate that those CLCLs are not restricted to cell lines.

110 **RESULTS**

111 Long read sequencing of cancer cell lines

112We conducted long read and whole genome sequencing analysis using the nanopore type 113sequencers, MinION and its latest high throughput derivative, PromethION. We first 114validated the performance of the new PromethION instrument by sequencing the 115genome of LC2/ad, which is a lung cancer cell line derived from a Japanese lung adenocarcinoma patient^{24,25} (Fig. 1 and Supplementary Table S1). As a reference, we 116117collected the whole genome sequencing data from a total of 33 MinION runs (R9.5 flow 118 cells) to cover the whole human genome at an overall sequencing depth of 31× by a total of 7,282,846 reads (93,813,338,154 base pairs (bp)). The maximum length and N50 119length of the reads were 2,495,160 bp and 30,606 bp, respectively. In total, 67.5 % of the 120 121reads were mapped to the human reference genome UCSC hg38 using Minimap2²⁶. The 122calculated overall sequence identity was 82 % on average. The average length of the 123mapped reads was 16,452 bp, which was significantly longer than previous long read whole human cancer genome sequencing analyses 27-29 (Table 1). The PromethION 124125sequencing required approximately three flow cells to generate a total of 10,064,668 126reads (100, 440, 433, 160 bp) for an overall coverage of $33 \times$ (Fig. 1) (this number 127decreased for subsequent cell types; see **Methods** for more details). The maximum 128length and N50 length of reads were 987,834 bp and 32,710 bp, respectively. Using 129Minimap2, 69.4 % of the reads were mapped to the reference genome. The average 130length of the mapped reads was 13,620 bp, and the average identity was 85 % (Table 1). 131Notably, because sample preparation need not be performed for each run, the required 132total amount of starting DNA used for PromethION could be reduced by more than 133 tenfold compared with MinION.

134To examine whether PromethION sequencing was compatible with MinION 135sequencing, we compared the features of the obtained two datasets. The overall distribution of read lengths was similar (Fig. 1A). Both datasets included a substantial 136137fraction of long reads over 50 kb (MinION: 360,786 reads, PromethION: 451,698 reads). 138Detailed analysis of the mapping results showed that more than 50 % of the human 139genome region was covered at more than 20× sequencing depth in both of the datasets 140(Fig. 1B). For the sequence accuracy, both datasets showed an overall fidelity of more than 80 % (Fig. 1C), which is similar to that of a previous study³⁰. We concluded that 141142PromethION should be an effective analytical method for whole cancer genome 143sequencing.

Having finished the initial evaluation of the data obtained from MinION and
PromethION, we scaled the MinION and PromethION sequencing for an additional four

146 lung cancer cell lines (A549, RERF·LC·KJ, RERF·LC·MS and PC·14; detailed cellular 147 profiles are described **Supplementary Table S1**). The data production proceeded 148 similarly to the case of LC2/ad cells, for example, in the sequencing of RERF·LC·KJ, 149 5,986,875 reads were generated (57,062,227,853 bp, at 18.5×), with the max and N50 150 lengths of the reads being 922,768 bp and 23,442 bp, respectively. Other detailed 151 statistics are shown in **Supplementary Figure S1** and **Supplementary Table S2**.

152To evaluate the quality of the sequence data at the individual base level, we 153examined the known driver mutations of the corresponding cells by manually reviewing the mapping results with Integrative Genomics Viewer (IGV)^{31,32}. In A549, eleven reads 154illustrated the cancerous mutation *KRAS* G12S as the point mutation (left, **Fig. 1D**). In 155PC-14, eight reads represented the driver NRAS Q61K point mutation (right, Fig. 1D). 156157Conversely, we also confirmed the absence of any driver mutations in the RERF-LC-KJ 158and RERF-LC-MS cell lines at well-known driver genes. All of these results are 159consistent with those of previous reports²³. These results collectively indicated that 160mutation calling at the single-base level is also possible using only the long read 161sequencer, at least when the cancer cell contents are as high as in the cultured cells.

162

163 Identification of large-scale genomic aberrations

164Using the long read sequencing data, we then attempted to detect structural aberrations larger than point mutations (Fig. 2A). From the MinION/PromethION 165166dataset of LC2/ad, we successfully identified 12 reads directly overlapping the junction 167point of the CCDC6-RET fusion gene, which is the known "cancer driver mutation" for 168this cell line^{24,25} (Fig. 2B) for details of the bioinformatics pipeline, see **Methods**). We 169 further attempted to identify large deletions. A large deletion around the CDKN2A gene, 170which is a well known tumor suppressor gene³, was previously reported to occur in LC2/ad, A549 and PC-14 cells²³ (Fig. 2C). Using the MinION/PromethION datasets in 171this study, we re-confirmed the deletion of this gene in the respective cells. In addition, 172173we found that the precise junction point of each of the CDKN2A deletions was different 174between the cell types. Large deletions in other cancer-related genes are described in 175Supplementary Figure S2.

We could also detect novel gene fusions by employing the split alignment method (see **Methods**). We identified three novel rearrangements, which were further validated by the Illumina short reads (**Fig. 2A** and **Supplementary Fig. S3**). These genes were fused to *NELL1-CCSER1* and *EFNA5-IKBKB* in LC2/ad and *UTS2B-GRM4* in RERF-LC-KJ. In each of these cases, the long read sequencing precisely identified the junction at single-base resolution (**Supplementary Table S3**).

182We further attempted to decipher perhaps the most difficult case, the 183rearrangement of the MYC gene. We identified copy number aberrations of the MYCgene in LC2/ad²³. The amplification was estimated to extend over approximately an 8 184185Mb locus having the MYC gene at the center. Even using long read sequencing, it was 186still difficult to completely reconstruct its structure, which included complex rearranged 187patterns, expanding to 8 Mb in chromosome 8 at an estimated aneuploidy of eight (Fig. 188**2D**). Particularly for the *MYC* region, we attempted to identify the correct structure by 189 the optical mapping method, Bionano Saphyr. Even using the Saphyr, the precise 190 structure of the MYC region remained elusive, though the results from this analysis support the MYC amplification spanning the 8 Mb region with approximately 8 copies 191192(**Fig. 2E**).

193

194 Identification of a new class of cancerous local genomic lesions, CLCL

195During the attempts to identify the above structural aberrations of the established 196classes, we unexpectedly found a new type of local structural aberration (Fig. 3). These 197aberrations consisted of complex combinations of copy number changes, inversions and 198deletions. As it appears that these aberrations do not precisely belong to the above 199categories, we named them Cancerous Local Copy number Lesions (CLCLs). As we will 200describe below, we found it difficult to identify and characterize these CLCLs regarding 201their precise junctions solely based on short read sequencing, even though some 202suggestive data could be occasionally obtained.

The first example was found in the *STK11* gene locus. In our previous study of lung cancer whole genome sequencing using Illumina, we noticed a possible local copy-number lesion in the *STK11* gene region in RERF-LC-KJ cells. The sequencing depth increased from the middle of intron 1 to the end of the gene²³. There were short read split tags (see Methods for details), suggesting that the inversions may occur in this region. Despite the substantial number of sequencing reads mapped in this region, we could not reconstruct its precise structure.

210We examined the long reads to decipher the aberration in the STK11 gene locus 211(Fig. 3A). It revealed the aberration as follows: The first rearrangement occurred as an 212inversion starting from intron 1 (chr19: 1,216,572; breakpoint II) and jumping 213downstream of the gene (chr19: 1,228,569; breakpoint IV). The inverted sequence 214continued back to the middle of the intron 1 (chr19: 1,216,360; breakpoint I), which was 215212 bases upstream of the initial breakpoint II. Then, the sequence reverted back and 216jumped to intron 3 (chr19: 1,219,538; breakpoint III). The following sequence continued 217to the end of the gene locus. The detected junctions, breakpoints II/IV and I/III, were represented by seven and nine PromethION reads, respectively. When we re-examined the Illumina reads, the sequencing depth increased at the two regions, between breakpoints I and II and between breakpoints III and IV (boxed region in **Fig. 3A**). We also looked for the short reads using the soft-clipped method. We found that it was difficult to detect two of the breakpoints, I and III, using the short read split tags, partly because the junctions were resided in the repetitive regions.

224

225 Identification of CLCLs in other genes and cell lines

To more generally identify CLCLs in other loci in all lung cancer cell lines, we constructed a new analytical bioinformatics pipeline (see **Supplementary Fig. S4** and **Methods**). Briefly, we utilized the information of the split alignments from the mapping results. We sorted the mapping information by the position of the reads and extracted the CLCL candidates. The associated reads were reassembled to reconstruct their structures.

232As a result, we successfully identified the following numbers of CLCLs in the 233other cell lines as well: sixteen in LC2/ad, one in A549, seven in RERF-LC-KJ, seven in 234RERF-LC-MS, and eleven in PC-14 (Table 2). Importantly, CLCLs were found to occur 235even in key cancer genes, such as the STK11, NF1, SMARCA4 and PTEN genes. The 236aberrant structures varied, and most of them would not be easily detected by the 237conventional short-read-based approaches because of their complex structures and the 238size of the affected regions. A relatively simple one was that which was detected in the 239*NF1* gene in RERF LC MS cells (**Fig. 3B**). This was a tandem duplication of the region between intron 9 (chr17:31,200,948) and the downstream region of the last exon 36 240241(chr17: 31,278,880; it was supported by six reads at the junction). In another case, the 242structure of the SMARCA4 CLCL showed a duplication from intron 1 (chr19:10,973,314) 243to intron 20 (chr19: 11,022,573; supported by eight reads at the junction; Fig. 3C). A more complex case was found in the structure of *PTEN* in PC-14. This CLCL was found 244245to be a combination of inversion and deletion (Fig. 3D). In these relatively simple cases, 246remapping of the Illumina short reads to the discovered junctions validated the precise 247identification of the reconstructed structure.

Indeed, although the presence of these mutations was partly suspected in a previous study²³, their precise structures remained elusive before this study. We and others had previously suspected the presence of large deletions, frameshift indels and splice site mutations based on short read sequencing for those cases. However, by conventional aberration detection based on the short reads, we could not detect some cases, which were first identified as CLCLs in this study (indicated by black dots in **Fig.** 254 **3E**).

We also examined the genomic context of the CLCLs. In total, 64 % (28/44) of the CLCLs had at least one junction overlapping with a long interspersed nuclear element (LINE), short interspersed nuclear element (SINE) or long terminal repeat (LTR), and 13 %, 24 % and 4 % (12/92, 22/92, and 4/92, respectively) of the junctions of the CLCLs were in a LINE, SINE or LTR, respectively (**Fig. 3F**). It is possible that their unique locations may hamper the precise identification of CLCLs by short read sequencing.

262

263 Aberrant transcriptional events associated with CLCLs

After the new CLCL-type aberrations were identified in a number of key genes in a number of cell types, the immediately raised question was in what manner they have transcriptional or epigenomic consequences.

267To characterize how the CLCL aberrations are reflected in the transcriptomes, we newly generated and analyzed full length cDNA sequencing data using MinION. We 268269also utilized the previous Illumina short read RNA-seq and ChIP-seq data. In 270RERF-LC-KJ cells, short read sequences indicated that the STK11 transcript is 271abnormally spliced at intron 1 and that transcription jumped just before the CLCL 272structure²³. MinION reads representing the full-length transcripts further specified the 273precise splice pattern and the transcription termination sites (Fig. 4A). For almost all of 274the transcripts, the first splicing occurred at the abnormal position (from 275chr19:1,216,268) and transcription occurred according to the CLCL structure (RNA-seq 276reads covered breakpoints II IV from chr19:1,216,572 to chr19:1,228,569). Some 277aberrant transcription was also observed within the downstream CLCL region (middle 278panel, Fig. 4A). Such an aberrant transcription pattern was not observed in PC-14 cells, 279where the *STK11* gene is wild type (lower panel, **Fig. 4A**).

280We examined the epigenome marks in the regions surrounding the CLCL as 281represented by the ChIP seq of H3K4me3, H3K9/14ac and RNA polymerase II. We 282found that chromatin normally formed the active structure at the promoter regions and 283that transcription was initiated normally at the correct position regardless of whether 284the cell line harbored the CLCL or wild type STK11 locus (Fig. 4B). However, in only the RERF-LC-KJ cells harboring the CLCL, the H3K36me3 mark disappeared in the 285286middle of intron 1, indicating that transcriptional elongation should be disrupted 287exactly where the CLCL started. Illumina RNA seq data also supported that the RNAs 288were abnormally spliced in the middle of intron 1 and transcribed according to the 289CLCL structure. The expression levels of these aberrant transcripts were measured as

290 2.8 rpkm. No normal transcripts were detected. However, the aberrant transcripts
291 retained a substantial expression level, although somewhat lower than that of the wild
292 type.

293We conducted a similar analysis for the other CLCLs. For the *PTEN* gene in PC-14 (Fig. 4C), the CLCL resided at exon 6. As a result, this exon was completely 294295skipped from the transcripts of *PTEN*. Accordingly, the resulting transcript should be 296frame shifted and thus should be likely to lead to functional loss of the *PTEN* gene. We 297also examined the RNA expression levels in the STK11, NF1, SMARCA4 and PTEN 298genes harboring CLCLs based on the Illumina RNA-seq data. The results indicated that 299CLCLs are generally likely to result in reduced gene expression levels (Fig. 4D). 300 Nevertheless, in some cases, gene expression levels remained significant, such as the 301 *NF1* transcripts in RERF-LC-MS cells and the *PTEN* transcripts in PC-14 cells.

302 To address the biological significance of the CLCLs, we examined how the 303 CLCL-affected locus invokes changes in protein expression levels and their related 304 signaling pathways. We conducted Western blotting analysis. As expected, we found 305 that the proteins of STK11, NF1, SMARCA4, and PTEN were completely lost in cells 306 harboring CLCLs in these genes (Fig. 4E). We further examined the activation status of 307 the downstream proteins. The expected disruptions of the pathways were observed for all of the examined cases. PTEN suppresses the phosphorylation of AKT, and 308 phosphorylated AKT (phospho-AKT) consequentially activates the mTOR signaling 309 310pathway³³. Aberrant upregulation of phospho-AKT was observed, reflecting the 311functional loss of PTEN in PC-14 cells (PTEN-CLCL). AMPK is a gene that plays an important role in maintaining cellular homeostasis, and the phosphorylation of the 312313 AMPK protein at its alpha subunit is activated by STK11³⁴. Its activation is impaired in RERF-LC-KJ cells (STK11-CLCL). The NF1 gene, which is a negative regulator of 314315RAS³⁵. Phospho-ERK, which is downstream of the RAS signaling pathway³⁶, was aberrantly upregulated in RERF-LC-MS cells (NF1-CLCL). Interestingly, despite the 316 317 clear protein losses of the corresponding genes in all of the cases, either by conventional 318aberrations or CLCLs, their consequences somewhat varied depending on the cases. For 319example, even though the STK11 protein similarly disappeared in both RERF·LC·MS 320 cells (STK11·loss) and RERF·LC·KJ cells (STK11·CLCL), the enhanced ratio of phospho-AMPKa was higher in the RERF-LC-KJ cells. The effects of NF1 in 321322RERF·LC·OK (NF1·loss) were almost undetectable, while the effects were significant in 323RERF-LC-MS cells (NF1-CLCL). It is possible that other pathways can sometimes 324complement the loss of the key protein.

325

326 Identification of CLCLs in clinical lung cancer specimens

327To examine whether CLCLs are also present in clinical cancer lung adenocarcinoma 328cases, we conducted similar PromethION whole genome sequencing for the surgical 329specimens of nine Japanese lung adenocarcinoma patients (Table 3 and Supplementary 330Table S4). The detected driver mutations for each patient are shown in Table 3. For 331these cases, we generated 43,953,136,203 bp sequences on average for each case (more than $10 \times$ depth; **Supplementary Table S5**). For case S10, we also sequenced normal 332333 counterparts to eliminate possible normal variations and dubious CLCLs derived from the mapping errors. 334

335Here, again, we successfully detected CLCLs. To our surprise, six of the nine 336 specimens harbored at least one CLCL in their tumor genomes. Again, several key 337 cancer genes were included. For example, we identified an *RNF20* CLCL in case S8. 338This patient is a female patient and had been shown to have an *EGFR* exon 19 deletion 339 as a driver mutation. However, the other cancerous mutations remained elusive. In this 340 case, the CLCL of the *RNF20* gene occurred as a tandem duplication between intron 2 341(chr9: 101,536,324) and intron 6 (chr9: 101,544,752, **Supplementary Fig. S5**), which is very likely to lead to the functional loss of this gene. The RNF20 gene encodes an E3 342ubiquitin ligase with a tumor suppressor function, and it is frequently mutated, 343particularly in lung cancer³⁷. In the other cases, the indications obtained for the 344molecular etiology underlying the carcinogenesis of the patients are summarized in 345346Table 3. Further scaling the long read sequencing would be needed to more precisely 347identify the frequencies of the CLCLs and the preference of the genes harboring CLCLs. 348

349 Re-evaluation of possible CLCLs based on public short read sequencing data

As the first step for scaling CLCL analysis, we attempted to utilize pre-existing Illumina short read data. We hoped that we might be able to identify CLCL candidates even from the short read sequence data. If this is possible, there are tens of thousands of whole-genome/exome sequencing datasets publicly available for the various cancer types. We were also interested in how these CLCLs had been represented by the previous short read sequences.

356To identify putative CLCLs starting from the short read sequences, we 357employed soft clipping GenomonSV а program, (https://github.com/Genomon Project/GenomonSV)38. We selected the "split" reads as 358359the "soft-clipped" reads and the paired end reads, which may span the junctions of the 360 SVs (see **Methods** for details). As the model dataset, we first analyzed the whole genome 361 short read data obtained for the five lung cancer cell lines that were used for the above 362 PromethION sequencing. We could extract an average of 182 "soft-clipped" junction 363 points in genic regions for each cell line (Supplementary Fig. S6). We defined tandem 364duplication structures as putative CLCLs in the short read data. An average of 26 genes 365were affected with putative CLCLs in the cell lines. We compared CLCLs detected from short reads with those from long reads (Supplementary Table S6). Among the CLCLs 366367 detected by PromethION, 72 % of the genes were also detected from the short read sequence data (Fig. 5A). However, the precision rates were limited to 25 % because of 368369 the general high rates of false positive detection.

We then collected and analyzed the whole-genome short read data at a sequencing depth of approximately 63× for nine clinical cases, as shown in **Table 3**. The obtained results were inspected regarding the possible occurrence of CLCLs. We identified an average of nine genes that may be affected by putative CLCLs. As shown in **Figure 5B**, CLCLs were detected starting from the short read data at an estimated sensitivity of 73 %. However, the precision rate was supposed to be limited to 14 % for a variety of reasons inherent to the shorter read sequencing.

377 Despite the limited estimated precision and recall rates of CLCL detection 378using short read data at 21 % and 72 %, respectively, for all the cell lines and clinical 379 samples taken together, we applied the constructed analytical pipeline to the 380 whole exome sequencing data of 514 TCGA lung adenocarcinoma (TCGA-LUAD)³ and 97 Japanese lung adenocarcinoma (Japanese LUAD)⁵ samples. We expected that the 381382detection rate would be inherently lower, reflecting the fact that they are exome 383 sequencing datasets. We detected a total of 269 and 50 junction points with tandem 384 duplication structures, which are likely to correspond to the CLCLs, by soft-clipped 385reads from TCGA-LUAD and Japanese LUAD cases, respectively (ranging from 1 to 29 genes per case). In total, we extracted CLCL candidates from 155 (30 %) TCGA-LUAD 386 387 and 39 (40 %) Japanese LUAD cases (Fig. 5C).

388In particular, we considered whether there were any suspected cases harboring 389 the CLCL candidates for the 299 genes that are considered to be the most relevant 390 "cancer associated genes" 39 . We detected 16 cases (2.6 % in 514 + 97 cases), harboring 391potential CLCLs in 17 genes (Fig. 5D). Interestingly, nine of these cases harbored no 392known driver mutations. For example, in the case of TCGA 49 4512 (female, nonsmoker), we identified a potential CLCL in the kinase domain of the EGFR gene. 393This duplication was previously reported⁴⁰ and might cause aberrant activation of 394395EGFR, thus serving as a driver mutation of this case. Importantly, this patient's 396 therapeutic target should be addressed by EGFR inhibitors such as afatinib⁴⁰. Putative 397 CLCLs associated with *ERBB2* were also detected in two other cases (both male and

398 smoked). Aberrant duplications seemed to occur between the *ERBB2* genic region and 399 the downstream intergenic or genic regions. Other patients were found to harbor 400 putative CLCLs in other important tumor suppressor genes, such as *STK11* and 401 *PBRM1*, for which mutation statuses could be utilized as putative markers for immune 402 checkpoint inhibitors⁴¹⁻⁴³. For these cases, the precise structure as well as the 403 functional relevance of the putative CLCLs are still unknown, and thus, they should be 404 subjected to detailed long read sequencing analyses.

405

406

407 DISCUSSION

In this paper, we have described the identification and characterization of structuralaberrations in lung cancer genomes using PromethION.

410We were able to identify the precise junctions of chromosomal rearrangements and large-scale deletions relatively easily. For example, the junction points of the 411 CDKN2A gene were precisely detected (Fig. 2C). In most cases, the proximal genes were 412413simultaneously deleted. In LC2/ad, the deletion spanned from the MIR31HG and MTAP 414gene loci to the DMRTA1 gene locus (supported by 9 reads). In A549 cells, the deletion 415started from the MTAP locus and reached the CDKN2B gene locus (supported by 15 reads). In PC-14, 22 genes were deleted in addition to the CDKN2A gene (supported by 4164178 reads). Several studies have reported that CDKN2A codeleted genes are involved in 418the hidden molecular features of cancers. The MTAP gene encodes 419 5-methylthioadenosine phosphorylase, which is associated with the purine and 420methionine salvage pathways, located to the adjacent region of the CDKN2A gene and 421frequently codeleted in cancers. MTAP deficient cancers are known to acquire vulnerability to arginine methyltransferase PRMT5 depletion, which may be a novel 422target of an anticancer drug⁴⁴⁻⁴⁶. It is important to determine the precise junction by the 423long read approach to completely understand what genes or regions are affected by 424425these genomic aberrations.

426We also identified the 8 Mb amplification for the MYC gene locus in LC2/ad 427cells. We attempted to further characterize it and found that even the latest long read 428sequencing technologies could not comprehend the precise mutation pattern in this 429locus. Eight Mb may have been too large, and the internal rearrangement may have 430been too complicated, although this is the only region where we could not reassemble 431the structure. Interestingly, we found no sequences suggesting aberrations occurring 432within the internal region of the MYC gene locus itself. Outside of the MYC gene, at 433 least four break points were detected by nanopore reads, which were further confirmed by the Illumina short reads (Fig. 2D). There may be a unique selective pressure exerted
on this gene specifically, retaining the gene function itself intact, at the same time,
enhancing its gene expression.

437Most importantly, in this study, we unexpectedly identified a unique aberration pattern, the CLCL. We found that CLCLs exist even in pivotal cancer-related genes, 438such as the STK11, NF1, SMARCA4, and PTEN genes. Recent papers have reported 439that immune checkpoint inhibitors are less effective for lung cancers with STK11 440441 mutations 41.42. Therefore, the therapeutic strategy for each patient would be different 442depending on whether there is a mutation in the STK11 gene or not. Additionally, CLCLs were identified in the PTPN13, RPTOR, and RHEB genes in LC2/ad cells (Table 443 2). *PTPN13* encodes a protein tyrosine phosphatase. The *RPTOR* and *RHEB* genes are 444445members of the mTOR signaling pathway. The functional loss of these genes should be 446related to tumorigenesis and malignancy of the cancer, although further studies will be 447needed to clarify the relationship between those aberrations and the molecular etiology of the cancers in more detail. 448

We could also analyze the causes and consequences of genomic SVs. In total, 67 % of the CLCLs had at least one junction in LINE, SINE and LTR regions, suggesting that transposable elements were likely to contribute to the formation of CLCLs. Using epigenome and transcriptome data, we also showed that CLCLs led to the formation of abnormal transcripts and functional loss of their encoded proteins in most cases.

455We further conducted long read sequencing of clinical samples. We successfully 456demonstrated that CLCLs occur in the *in vivo* genomes of lung adenocarcinoma patients. 457In six cases, at least one CLCL was detected in the genes of important functions, giving 458the complementary therapeutic indication for the patients. Finally, we reanalyzed short 459read sequencing data from clinical samples that were previously published^{3,5}, particularly focusing on detecting CLCLs in cancer-related genes, such as the driver 460461 genes of lung adenocarcinoma. Although the current precision rate is limited, the recall 462rate was reasonably high. We believe it is important to subject those cases to further detailed long read sequencing. We suggest that CLCLs occurring in cancer genomes 463464might have important roles in the phenotypic features of cancers, including responses to 465anticancer drugs.

Lastly but not less importantly, we found that the visualization of the detected mutation is also important. So-called "genome graph" databases should play an indispensable role in representing the diverse nature of cancer genomes and thus further enhance the accuracy of future genome analyses^{47,48}. This is the first study that

470 has utilized PromethION sequencing for cancer genomics. Obviously, further 471 improvements in the sequencing method itself, coupled with refinements of the 472 computational tools, are needed to reach further goals. Indeed, this study may have 473 presented more questions than answers. In that sense, this is only the first study 474 paving the way towards a more comprehensive understanding of the complicated 475 genomic aberrations of cancers and further in depth study of their biology.

476 MATERIAL AND METHODS

477 *Cell lines and clinical samples*

478 The Lung adenocarcinoma cell lines LC2/ad, A549, RERF-LC-KJ, RERF-LC-MS, and

479 PC·14 were cultured as previously described²³. Cell pellets were washed with cold PBS
480 and cryopreserved.

Clinical samples were obtained with the appropriated informed consent at the National Cancer Center Japan. Surgical specimens from 10 patients were pathologically checked, and one was removed because of low tumor content (Supplementary Fig. S7 and Supplementary Table S4). All nine patients were diagnosed with primary lung cancer, including eight adenocarcinomas and one large cell carcinoma (Table 3). Fresh frozen surgical specimens were used to extract genomic DNA (gDNA) and total RNA as described below.

488

489 Whole-genome sequencing using MinION

High-molecular-weight (HMW) gDNA was extracted from the lung cancer cell lines 490491LC2/ad and A549 with Smart DNA prep(a) kit (Analytikjena). In the case of LC2/ad, 492WGS data were produced from 1D sequencing (SQK-LSK108), 1D² sequencing 493(SQK-LSK308), rapid sequencing (RAD003), and in the case of A549, WGS data were 494produced from only 1D² sequencing. In summary, 4 µg HMW gDNA was used for 1D 495sequencing and DNA repair, end-prep, and adapter ligation were conducted. DNA repair 496 was performed using NEBNext FFPE DNA Repair Mix (M6630, NEB). End prep was 497performed using NEBNext Ultra II End Repair/dA-Tailing Module (E7546L, NEB). 498Adapter ligation was performed using NEBNext Blunt/TA Ligase Master Mix (M0367L, NEB) and Ligation Sequencing Kit 1D (SQK-LSK108, Oxford Nanopore Technologies). 499In summary, $1D^2$ sequencing, 4 or 5 µg HMW gDNA was used as input, and DNA repair, 500501end prep, first adapter ligation, and second adapter ligation were conducted. DNA repair and end prep were the same protocol as the 1D sequencing. First and second 502503adapter ligations were performed using NEBNext Blunt/TA Ligase Master Mix and 504Ligation Sequencing Kit 1D² (SQK·LSK308, Oxford Nanopore Technologies). DNA purifications in each step of 1D and $1D^2$ sequencing were performed using Agencourt 505506AMPure XP (A63882, Beckman Coulter). In summary, 15 µl gDNA was used for rapid sequencing, and a Rapid Sequencing Kit (RAD003) was used. 507

508

509 Whole-genome sequencing using PromethION

- 510 The HMW gDNA extraction method was the same as MinION sequencing for LC2/ad,
- 511 A549, and RERF-LC-MS. Forty-eight microliters of 1.5 or 2 µg gDNA plus nuclease free

512water (NFW), 3.5 µl of NEBNext FFPE DNA Repair Buffer, 2 µl of NEBNext FFPE DNA 513Repair Mix (M6630, NEB), 3.5 µl of NEBNext Ultra II End Prep Reaction Buffer, and 3 514µl of NEBNext Ultra II End Prep Enzyme Mix (E7545L, NEB) were mixed gently in 1.5 515ml Eppendorf tube. After spinning down, the sample was incubated at 20 °C for 5 minutes and 65 °C for 5 minutes. Then, 60 µl of AMPure XP beads (A63882, Beckman 516517Coulter) was added to the tube and the tube was mixed by flicking. The sample was incubated for 5 minutes at room temperature (R.T.) using a rotator mixer. After 518519spinning down, the tube was set on a magnetic stand, and the supernatant was pipetted 520off. The beads were washed twice with 200 µl of 70 % ethanol. The tube was spun down and back on the magnet. Any residual ethanol was pipetted off, and the tube was dried 521522for 30 seconds. The tube was removed from the magnetic stand, the pellet was 523resuspended in 61 µl NFW, and the tube was incubated for 2 minutes. The tube was set 524on a magnet, 60 μ l of the sample was used in the next step, and 1 μ l was used for quality 525check by Qubit. 60 µl of end prepped DNA, 25 µl of Ligation Buffer (LNB), 10 µl of NEBNext Quick T4 DNA Ligase (NEB, E6056S), and 5 µl of Adapter Mix (AMX) were 526527mixed in a 1.5 ml Eppendorf tube. After spinning down, the sample was incubated at 528R.T. for 10 minutes. Then, 40 μ l of AMPure XP beads was added to the tube and mixed 529by flicking. The sample was incubated for 5 minutes at R.T. using a rotator mixer. After 530spinning down, the tube was set on the magnetic stand. The supernatant was pipetted off, and the beads were washed twice with 250 µl of Fragment Buffer (LFB). The sample 531532was spun down, and the tube was replaced on the magnet. Any residual supernatant 533was pipetted off, and the tube was dried for 30 seconds. The tube was removed from the 534magnet, and the pellet was resuspended in $25 \,\mu$ l of Elution Buffer (EB). The sample was 535incubated at R.T. for 10 minutes. Next, 24 µl of the sample was used in the next step, and 1 µl was used for quality check by Qubit. A total of 46 µl of Flush Tether (FLT) was 536537added directly to the tube of PromethION Flush Buffer (PFB), and the solution was mixed by pipetting (Priming Mix). Then, 800 µl of Priming Mix was loaded onto the 538539PromethION flow cell. Next, 75 µl of SQB, 51 µl of LB, and 24 µl of the DNA library 540were mixed in a 1.5 ml Eppendorf tube in 5 minutes (Loading Library). Then, 200 µl of Priming Mix was loaded onto the flow cell, and 150 µl of Loading Library was loaded 541542onto the flow cell. We started the PromethION run. The LNB, AMX, LFB, EB, FLT, PFB, SQB, and LB are in Ligation Sequencing Kit 1D (SQK-LSK109, Oxford Nanopore 543Technologies). From RERF-LC-KJ, PC-14, and lung adenocarcinoma clinical samples, 544545HMW gDNA was extracted with the MagAttract HMW DNA Kit (Qiagen). For the 546LC2/ad cells, we performed five runs, and each throughput was 10.4 Gb, 9.2 Gb, 33.0 Gb, 54728.5 Gb, and 19.3 Gb, respectively.

548

549 Full-length transcriptome sequencing using MinION

Full-length transcriptome analysis using MinION was performed as previously
described⁴⁹. RNA was extracted from lung cancer cell lines using the RNeasy Mini kit
(Qiagen). The extracted RNA was converted to cDNA using SMART-seq v4 Ultra Low
input RNA kit (Takara). Then, we used cDNA as input for 1D² MinION sequencing.

554

555 Computational analysis of long read sequencing data

556MinION fast5 data were basecalled using albacore 2.0.2 and converted fastq files. PromethION fast5 data were basecalled using guppy and converted fastq files. Our 557MinION and PromethION data set were mapped to the human reference genome, hg38, 558using Minimap2 (with the "ax map ont" option, 2.9 r720 version). MinION 1D² 559sequencing outputs two types of fastq files, 1D and 1D². 1D means that reads were 560generated using single strand information. $1D^2$ reads integrate the double strand 561562information. There were some overlapping reads between 1D files and $1D^2$ files. 563 Therefore, reads used as $1D^2$ were removed from 1D files. In addition, there were some overlapping reads in the $1D^2$ files. These reads were removed from the $1D^2$ files and 564565used as 1D reads.

566

567 Detection of driver mutations for cell lines in long read data

568We detected known driver mutations by IGV. For the point mutations, we directly 569explored the known positions of the mutations. For the driver mutation of LC2/ad cells, 570the $CCDC6 \cdot RET$ fusion gene, we explored the reads split-aligned to both RET and CCDC6 genes in the reference genome and extracted the alignments with SAM format 571572from IGV. Then, we extracted the information of split alignment (chromosome, position 573of reference, read strand, and position of read) from the file and sorted the information by the position of reads. We filtered out reads with small MAPQ (< 30) and counted the 574575number of supporting reads.

576

577 Detection of structural variants from long read data

578 To detect gene rearrangements and CLCLs, we used the information of split alignments.

579 First, we mapped sequencing data (fastq) to the human reference genome, hg38. Then,

580 we extracted reads with split alignment from mapping data (bam) using the command

581 "samtools view ·f 2048". We filtered out reads with multiple hits (flag: 256). Then, we

- 582 extracted the information of split alignments (chromosome, position of reference, read
- 583 strand, and position of read) from the file and sorted the information by the position of

reads. We filtered out reads with low MAPQ (< 30) from the dataset. We extracted 584585junction candidates of gene rearrangements and CLCLs (tandem duplications and 586inversions) considering the position of reads (removing junctions with large differences 587in read position, >300 bp), annotated the junctions by genes from DBKERO (http://kero.hgc.jp/) and merged the junctions less than 50 bp from the junctions of 588589CLCL candidates. The threshold for the number of reads supporting the junctions was four in the clinical samples and five in the cell lines. We removed junctions with less 590591than 2,000 bp between the junctions. Finally, we checked the structure of the candidates 592for gene rearrangements and CLCLs by IGV and manually removed questionable 593rearrangements and CLCLs. To detect deletions, we used the information of split 594alignments and CIGAR strings in SAM format files. We extracted the information of 595split alignments in the same way as the detection of gene rearrangements and CLCLs. We extracted the CIGAR strings from reads with primary alignments using SAMtools 596597 (flags: 0 or 16). Then, we detected deletions over 2,000 bp.

598

599 Optical mapping using the Saphyr system

Optical mapping analysis using the Saphyr system (Bionano Genomics) was performed
for LC2/ad cells. Briefly, HMW DNAs were isolated from frozen cells using a Bionano
Prep kit (Bionano Genomics) and measured by Qubit BR assay (Invitrogen). The
extracted DNAs were fluorescently labeled with DLE-1 using a Bionano DLS kit
(Bionano Genomics). Data were collected on the Saphyr instrument (Bionano Genomics).
The figures were created by Bionano Access (version 1.3.0, Bionano Genomics).

606

607 Western blotting

608 We performed Western blotting as described previously to quantify proteins from genes 609 with CLCL structures⁵⁰. For Western Blotting, we performed protein extraction and quantification. We used a Pierce BCA Protein Assay kit (23225, Thermo Fisher 610 611 SCIENTIFIC) and prepared proteins of 1 mg/ml. In summary, we performed 612electrophoresis of proteins, membrane transferring, blocking, reaction of the first antibody, reaction of the second antibody, and visualization of bands. We conducted 613614 electrophoresis using a tank and used 10 or 15 µl of proteins as input. For blocking, we used 4 % BSA blocking buffer. In the reaction of the first antibody, we used LKB1 615(27D10) Rabbit mAb (3050S, CST) for STK11, phospho-AMPK alpha(Thr172) Antibody 616(2535S, CST) for phospho AMPKa, AMPK alpha Antibody Rabbit mAb (2603S, CST) for 617AMPKa, Anti-Neurofibromin (NF1) (rabbit polyclonal IgG) (07.730, upstate) for NF1. 618 619 Phospho-p44/42 MAPK (Erk1/2) (Thr202/Thr204) (E10) Mouse mAb (9106S, CST) for

phospho-ERK, p44/42 MAPK (Erk1/2) Antibody (9102S, CST) for ERK, Brg1 (D1Q7F) 620 621Rabbit mAb (49360, CST) for SMARCA4, PTEN (138G6) Rabbit mAb (CST, 9559S) for PTEN protein, Phospho-Akt (Ser473) (D9E) XP[®] Rabbit mAb (4060S, CST) for 622 623 phospho-AKT, and Akt (pan) (11E7) Rabbit mAb (4685S, CST) for AKT. As a control, we 624used GAPDH and GAPDH (14C10) Rabbit mAb (2118S, CST) as an anti-body. In the 625reaction of the second antibody, we used an antibody corresponding to the animal that generated the first antibody. We used Anti-rabbit IgG, HRP-linked antibody (7074S, 626627 CST) for rabbit and Anti-mouse IgG, HRP-linked antibody (7076S, CST) for mouse. For 628 the visualization of bands, we used ImageQuant LAS 4000 mini (GE Healthcare). The 629 normalized ratio indicated the fraction of relative density of phosphorylated protein to 630 control protein and relative density of total protein to control protein, and we set the 631normalized ratio of the wild type as one (Fig. 4E). The density of the bands was 632calculated by ImageJ software⁵¹.

633

634 Whole-genome short read sequencing of clinical samples

635 Genomic DNA was extracted from surgical specimens using the MagAttract HMW DNA 636 Kit (QIAGEN). Whole genome sequencing libraries were constructed using the TruSeq 637 Nano DNA Library Prep kit (Illumina) and sequenced by NovaSeq according to the 638 manufacturers' instructions. In summary, 100 ng gDNA was used for library preparation as input, and DNA fragmentation, end repair, adenylation of the 3' end, 639640adapter ligation, and condensation of DNA fragments were conducted. We performed 641DNA fragmentation using Covaris (Covaris) and used a protocol for 350 bp of insert size. 642After preparing the library, we denatured the library with NaOH and then started the 643 NovaSeq run.

644

645 Analysis of short read sequencing data

Whole-genome short read sequences were mapped to the human reference genome
(hg38) using BWA-MEM (version 0.7.15). After mapping, sorted BAM files were created,
and PCR duplicates were marked by SAMtools. For detection of driver mutations in the
ten clinical samples, point mutations and variations were called using GATK Mutect2
(version 4.0.12.0).

For transcriptome and epigenome analysis of the cell lines, we used RNA-seq and ChIP-seq data that were previously obtained (DRA001846 and DRA001860) and mapped to the reference genome hg19. IGV was used for visualization.

To detect SV junctions, GenomonSV (version 2.6.1) was used with paired end read sequencing data as listed; 5 whole-genome datasets from cancer cell lines 656 (DRA001859; 101PE, Illumina HiSeg2500), nine whole genome datasets from Japanese 657lung cancer patients (150PE, Illumina NovaSeq), 514 whole exome datasets from 658TCGA·LUAD and 97 whole exome datasets from Japanese lung adenocarcinoma 659patients (JGAS0000000001; 76PE, Illumina GAIIx). After conducting Genomon 2.6.1)660 (version with therecommended parameters 661 (https://genomon.readthedocs.io/ja/latest/; reference: hg19), GenomonSV filt was performed with the options "...min_junc_num 1" and "...non_matched_control_junction" 662663 with control panels that were constructed from ICGC/TCGA data. For clinical samples 664 harboring matched normal data, we also set the option "--matched control bam". For 665 the cell lines, matched normal data of case S1 were used for normal control data. After GenomonSV filt, we eliminated SV candidates with tumor VAF < 0.05 and a distance of 666 667 less than 2 kb between the junctions. We analyzed at least one SV junction within genic 668regions. For validation of SVs, junction points were compared between long read and 669 short read data, allowing 100-bp margins after performing conversion of the reference 670genome version (https://genome.ucsc.edu/cgi/bin/hgLiftOver).

671Genes with putative CLCLs are defined as those affected by SV junctions with 672a tandem duplication structure. To evaluate the detection power of short read data, 673 genes with CLCL (and putative CLCLs) were classified into three categories: true 674positives detected in both long read and short read data; false positives detected in short read data only; and false negatives detected in long read data only. The precision and 675676recall rates of CLCL detection of short read data were calculated using the number of 677true positives, false positives and false negatives. For CLCLs in cancer-related genes, 678 we checked 299 cancer related genes that were previously reported as cancer driver 679 genes. The cancer driver genes were classified in gene types as follows: genes significant in lung adenocarcinoma and pan-cancer types as "LUAD and multiple cancer types", 680 681 genes significant in multiple and pan-cancer types as "Multiple cancer types", and genes significant in other cancer types than lung adenocarcinoma as "Unique to other cancer 682types"³⁹. For known driver mutation status, 13 genes (EGFR, KRAS, BRAF, HRAS, 683 NRAS, RET, MAP2K1, ALK, ROS1, ERBB2, MET, NF1 and RIT1) were examined in 684 the 16 cases by cBioPortal (Lung adenocarcinoma; TCGA; PanCancer Atlas)⁵²⁻⁵⁴. 685

 $\begin{array}{c} 686 \\ 687 \end{array}$

688 DATAACCESS

All sequencing data of cell lines were published in the DNA Data Bank of Japan (DDBJ)
under the accession numbers, DRA007423 (DRX143541, DRX143542, DRX143543,
DRX143544), DRA007941, DRA008154 and DRA008295. The data were also deposited

in DBKERO (https://kero.hgc.jp)⁵⁵. Sequencing data of clinical samples were deposited
at the Japanese Genotype-phenotype Archive (JGA, http://trace.ddbj.nig.ac.jp/jga),
which is hosted by the National Bioscience Database Center (NBDC) and DDBJ, under
the accession numbers, JGAS0000000065 (JGAD0000000252 and
JGAD0000000253).

- 697
- 698

699 ACKNOWLEDGEMENTS

700 We thank K. Imamura, K. Abe, M. Kimura, H. Wakaguri, Y. Kuze and T. Horiuchi for 701 their technical assistance. The Bionano data were generated at Bionano Genomics and 702K. Hong and A. Pang collected and analyzed the data. This work was supported by AMED P-CREATE Grant Number JP19cm0106539. This work was also supported in 703 704 part by The National Cancer Center Research and Development Fund (29-A-6). This 705work was also supported by JSPS KAKENHI Grant Number 16H06279. The results 706shown in this study are in part based on data generated by the TCGA Research 707Network (https://www.cancer.gov/tcga). The super-computing resource was provided by 708 Human Genome Center, the University of Tokyo (http://sc.hgc.jp/shirokane.html).

709

710

711 AUTHOR CONTRIBUTIONS

Y. Sakamoto, A.S. and Y. Suzuki designed the study. Y. Sakamoto, L.X., and M.S.
performed sequencing experiments. Y. Sakamoto, T.K., M.K., Y. Shiraishi and A.S.
contributed computational analysis of sequencing data. Y. Sakamoto, Y.K., A.O. and S.K.
conducted Western blotting. Y. Shimada, N.M. and T.K. contributed and analyzed
clinical specimens. K.T., S.K., T.K. and Y. Suzuki interpreted the findings and
supervised the study. Y. Sakamoto, A.S. and Y. Suzuki wrote the manuscript. All
authors approved the final version of the manuscript.

719 720

721 COMPETING INTERESTS

722 The authors declare no competing interests.

723

724

725 **REFERENCES**

Hudson, T. J. *et al.* International network of cancer genome projects. *Nature* 464, 993–998 (2010).

728	2.	The Cancer Genome Atlas Research Network <i>et al.</i> The Cancer Genome Atlas
729		Pan-Cancer analysis project. <i>Nat. Genet.</i> 45 , 1113–1120 (2013).
730	3.	The Cancer Genome Atlas Research Network. Comprehensive molecular profiling of
731		lung adenocarcinoma. <i>Nature</i> 511 , 543–550 (2014).
732	4.	Seo, J. S. et al. The transcriptional landscape and mutational profile of lung
733		adenocarcinoma. <i>Genome Res.</i> 22, 2109–2119 (2012).
734	5.	Suzuki, A. et al. Identification and Characterization of Cancer Mutations in Japanese
735		Lung Adenocarcinoma without Sequencing of Normal Tissue Counterparts. $PLoS$
736		<i>One</i> 8 , e73484 (2013).
737	6.	Imielinski, M. et al. Mapping the hallmarks of lung adenocarcinoma with massively
738		parallel sequencing. <i>Cell</i> 150 , 1107–1120 (2012).
739	7.	Kohno, T. et al RET fusion gene: Translation to personalized lung cancer therapy.
740		Cancer Sci 104, 1396–1400 (2013).
741	8.	Yoh, K. et al Vandetanib in patients with previously treated RET rearranged
742		advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2
743		trial. Lancet Respir. Med. 6, 2–10 (2016).
744	9.	Mainardi, S. <i>et al</i> SHP2 is required for growth of KRAS mutant non-small-cell lung
745		cancer in vivo. <i>Nature Medicine</i> 1–7 (2018). doi:10.1038/s41591·018·0023·9
746	10.	Ruess, D. A. et al. Mutant KRAS driven cancers depend on PTPN11/SHP2
747		phosphatase. <i>Nature Medicine</i> 1–7 (2018). doi:10.1038/s41591-018-0024-8
748	11.	Wong, G. S. et al Targeting wild type KRAS amplified gastroesophageal cancer
749		through combined MEK and SHP2 inhibition. <i>Nature Medicine</i> 1–10 (2018).
750		doi:10.1038/s41591-018-0022-x
751	12.	Treangen, T. J. & Salzberg, S. L. Repetitive DNA and next-generation sequencing:
752		Computational challenges and solutions. Nature Reviews Genetics 13, 36–46 (2012).
753	13.	Pleasance, E. D. et al. A comprehensive catalogue of somatic mutations from a
754		human cancer genome. <i>Nature</i> 463 , 191–196 (2009).
755	14.	Liu, S. et al. Comprehensive evaluation of fusion transcript detection algorithms and
756		a meta-caller to combine top performing methods in paired end RNA-seq data.
757		Nucleic Acids Res. 44, (2015).
758	15.	Guan, P. & Sung, W. K. Structural variation detection using next-generation
759		sequencing data: A comparative technical review. <i>Methods</i> 102 , 36–49 (2016).
760	16.	Ardui, S., Ameur, A., Vermeesch, J. R. & Hestand, M. S. Single molecule real-time
761		(SMRT) sequencing comes of age: applications and utilities for medical diagnostics.
762		Nucleic Acids Res. (2018). doi:10.1093/nar/gky066
763	17.	Cavelier, L. et al Clonal distribution of BCR-ABL1 mutations and splice isoforms by

764		single-molecule long-read RNA sequencing. <i>BMC Cancer</i> 15 , 45 (2015).
765	18.	Davis, C. F. et al. The somatic genomic landscape of chromophobe renal cell
766		carcinoma. <i>Cancer Cell</i> 26 , 319–330 (2014).
767	19.	Ishiura, H. et al. Expansions of intronic TTTCA and TTTTA repeats in benign adult
768		familial myoclonic epilepsy. <i>Nat. Genet.</i> 50 , 581–590 (2018).
769	20.	Norris, A. L., Workman, R. E., Fan, Y., Eshleman, J. R. & Timp, W. Nanopore
770		sequencing detects structural variants in cancer. Cancer Biol. Ther. 17, 246–253
771		(2016).
772	21.	Suzuki, A. et al Sequencing and phasing cancer mutations in lung cancers using a
773		long-read portable sequencer. DNA Res. 24, 585–596 (2017).
774	22.	Oikonomopoulos, S., Wang, Y. C., Djambazian, H., Badescu, D. & Ragoussis, J.
775		Benchmarking of the Oxford Nanopore MinION sequencing for quantitative and
776		qualitative assessment of cDNA populations. Sci. Rep. 6, (2016).
777	23.	Suzuki, A. et al Aberrant transcriptional regulations in cancers: Genome,
778		transcriptome and epigenome analysis of lung adenocarcinoma cell lines. <i>Nucleic</i>
779		Acids Res. 42, 13557–13572 (2014).
780	24.	Suzuki, M. $et al.$ Identification of a lung adenocarcinoma cell line with CCDC6-RET
781		fusion gene and the effect of RET inhibitors in vitro and in vivo. Cancer Sci. 104,
782		896–903 (2013).
783	25.	Matsubara, D. et al. Identification of CCDC6-RET fusion in the human lung
784		adenocarcinoma cell line, LC·2/ad. J. Thorac. Oncol. 7, 1872–1876 (2012).
785	26.	Li, H. Minimap2: pairwise alignment for nucleotide sequences. <i>Bioinformatics</i> 1–7
786		(2018). doi:10.1101/169557.
787	27.	Seo, J. S. et al. De novo assembly and phasing of a Korean human genome. Nature
788		538 , 243–247 (2016).
789	28.	Shi, L. et al. Long-read sequencing and de novo assembly of a Chinese genome. Nat.
790		Commun 7, (2016).
791	29.	Mizuguchi T, Suzuki T, Abe C, Umemura A, Tokunaga K, Kawai Y, Nakamura M,
792		Nagasaki M, Kinoshita K, Okamura Y, Miyatake S, Miyake N, M. N. A 12•kb
793		structural variation in progressive myoclonic epilepsy was newly identified by
794		long-read whole-genome sequencing. J. Hum. Genet. (2019).
795	30.	Jain, M. et al Nanopore sequencing and assembly of a human genome with
796		ultra·long reads. <i>Nat. Biotechnol</i> 36 , 338–345 (2018).
797	31.	Robinson, J. T. <i>et al.</i> Integrative Genome Viewer. <i>Nat. Biotechnol.</i> 29 , 24–6 (2011).
798	32.	Thorvaldsdóttir, H., Robinson, J. T. & Mesirov, J. P. Integrative Genomics Viewer
799		(IGV): High performance genomics data visualization and exploration. Brief

800		Bioinform. 14, 178–192 (2013).
801	33.	Carracedo, A., Salmena, L. & Pandolfi, P. P. SnapShot: PTEN Signaling Pathways.
802		<i>Cell</i> 133 , 550–550.e1 (2008).
803	34.	Mihaylova, M. M. & Shaw, R. J. The AMP-activated protein kinase (AMPK) signaling
804		pathway coordinates cell growth, autophagy, & metabolism. <i>Nat. Cell Biol.</i> 13,
805		1016–1023 (2012).
806	35.	Wolman, M. A. et al. Modulation of cAMP and Ras Signaling Pathways Improves
807		Distinct Behavioral Deficits in a Zebrafish Model of Neurofibromatosis Type 1. <i>Cell</i>
808		<i>Rep.</i> 8 , 1265–1270 (2014).
809	36.	De Luca, A., Maiello, M. R., D'Alessio, A., Pergameno, M. & Normanno, N. The
810		RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer
811		pathogenesis and implications for the rapeutic approaches. <i>Expert Opin. Ther.</i>
812		Targets 16, S17–S27 (2012).
813	37.	Sethi, G., Shanmugam, M. K., Arfuso, F. & Kumar, A. P. Role of RNF20 in cancer
814		development and progression – a comprehensive review. <i>Biosci. Rep.</i> 38,
815		BSR20171287 (2018).
816	38.	Kataoka, K. et al. Aberrant PD-L1 expression through 3'-UTR disruption in multiple
817		cancers. <i>Nature</i> 534 , 402–406 (2016).
818	39.	Bailey, M. H. et al. Comprehensive Characterization of Cancer Driver Genes and
819		Mutations. Cell 173, 371-385.e18 (2018).
820	40.	Gallant, J. N. $et al$ EGFR kinase domain duplication (EGFR ·KDD) is a novel
821		oncogenic driver in lung cancer that is clinically responsive to a fatinib. Cancer Discov.
822		5 , 1155–1163 (2015).
823	41.	Rizvi, H. et al. Molecular determinants of response to anti-programmed cell death
824		(PD)·1 and anti-programmed death-ligand 1 (PD·L1) blockade in patients with
825		non-small-cell lung cancer profiled with targeted next-generation sequencing. J. Clin.
826		<i>Oncol.</i> 36 , 633–641 (2018).
827	42.	Skoulidis, F. et al STK11/LKB1 mutations and PD·1 inhibitor resistance in
828		KRAS-mutant lung adenocarcinoma. <i>Cancer Discov.</i> 8 , 822–835 (2018).
829	43.	Miao, D. et al. Genomic correlates of response to immune checkpoint therapies in
830		clear cell renal cell carcinoma. <i>Science (80).</i> 359 , 801–806 (2018).
831	44.	Kryukov, G. V. <i>et al.</i> MTAP deletion confers enhanced dependency on the PRMT5
832		arginine methyltransferase in cancer cells. <i>Science (80).</i> 351 , 1214–1218 (2016).
833	45.	Mavrakis, K. J. et al Disordered methionine metabolism in MTAP/CDKN2A-deleted
834		cancers leads to dependence on PRMT5. Science (80). 351, 1208–1213 (2016).
835	46.	Marjon, K. et al. MTAP Deletions in Cancer Create Vulnerability to Targeting of the

~ 11 D

836		MAT2A/PRMT5/RIOK1 Axis. <i>Cell Rep.</i> 15 , 574–587 (2016).
837	47.	Garrison, E. et al. Variation graph toolkit improves read mapping by representing
838		genetic variation in the reference. Nat. Biotechnol. 36, 875–881 (2018).
839	48.	Rakocevic, G. et al Fast and Accurate Genomic Analyses using Genome Graphs. Nat.
840		Genet. 194530 (2019). doi:10.1101/194530
841	49.	Seki, M. et al Evaluation and application of RNA-Seq by MinION. DNA Res. (2019).
842		doi:10.1093/dnares/dsy038
843	50.	Ohashi, A. et al. Aneuploidy generates proteotoxic stress and DNA damage
844		concurrently with p53-mediated post-mitotic apoptosis in SAC-impaired cells. $\it Nat$
845		<i>Commun</i> 6 , 1–16 (2015).
846	51.	Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of
847		Image Analysis HHS Public Access. Nat. Methods 9, 671–675 (2012).
848	52.	Gao, J. et al Integrative analysis of complex cancer genomics and clinical profiles
849		using the cBioPortal. Sci. Signal 6, (2013).
850	53.	Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring
851		multidimensional cancer genomics data. Cancer Discov. 2, 401–4 (2012).
852	54.	Hoadley, K. A. et al. Cell-of-Origin Patterns Dominate the Molecular Classification of
853		10,000 Tumors from 33 Types of Cancer. <i>Cell</i> 173 , 291–304.e6 (2018).
854	55.	Suzuki, A. et al DBTSS/DBKERO for integrated analysis of transcriptional
855		regulation. <i>Nucleic Acids Res.</i> 46 , D229–D238 (2018).
OFC		

856 857

~ ~ ~

858 FIGURE LEGENDS

859 Figure 1 Long read sequencing of cancer genomes

(A) Left: raw read length distribution of LC2/ad MinION sequencing. Right: raw read 860 length distribution of LC/2ad PromethION sequencing. Both MinION and PromethION 861 862 datasets have many long reads (for example, over 50 kb, 361 K reads and 452 K reads, 863 respectively). (B) Cumulative depth curve of LC2/ad. Blue: PromethION, Red: MinION. 864 More than 50 % of the human genome region was covered by more than $20 \times$ in sequencing depth in both of the datasets. (C) Violin plots of identity of LC/2ad MinION 865866 sequencing (left) and PromethION sequencing (right). The points in the violin plots 867 indicate the average identities of the MinION and PromethION data (82.1 %, 84.8 %, respectively, Table 1). The identities were concentrated at more than 80 % in both 868 datasets. (D) IGV image of point mutations in the driver genes KRAS and NRAS in 869 MinION/PromethION sequencing (upper) and in Illumina sequencing (lower). KRAS 870 871 point mutation (G12S) is a driver mutation in A549 cells and NRAS point mutation 872 (Q61K) is a driver mutation in PC-14 cells.

873

874 Figure 2 Long read sequencing reveals structural variants

875 (A) Circos plot of novel rearrangement candidates in LC2/ad. The second layer of the Circos plot indicates the sequencing depth by MinION. Detailed information on this 876877 rearrangement is shown in Supplementary Table S3. (B) IGV image of the CCDC6-RET fusion gene of LC2/ad MinION sequencing. The CCDC6-RET fusion gene is a driver 878879 mutation of LC2/ad cells. The number of reads supporting the junction is twelve. (C) 880 IGV image of a large deletion including CDKN2A of LC2/ad, A549, and PC-14. The 881 deletion of LC2/ad spanned approximately 941 kb. The deletion of A549 spanned approximately 296 kb. The deletion of PC-14 spanned approximately 3,438 kb. The 882 883 parentheses indicate the range of length of reads supporting the deletions. (D) Depth 884 plotting around the MYC gene of LC2/ad. Arrows indicate junction candidates of the 885 amplification supported by MinION and Illumina reads. 0: the number of supporting MinION reads (left) and Illumina paired end reads (right). (E) The 8-copy MYC region 886 887 of LC2/ad represented by the optical mapping method. Optical maps with 888 rearrangements and chromosome 8 (reference) are represented in light blue and 889 yellow green, respectively. The orange arrow indicates the MYC gene.

890

891 Figure 3 Identification and characterization of CLCL

(A) Structure of the STK11 CLCL in RERF·LC·KJ. The STK11 CLCL was constructed 892 893 by a combination of local inversions. We can trace the CLCL structure following the 894 ordered arrows, and the junctions are indicated by colored arrows. The CLCL spanned 895 12 kb in the human reference genome. (B) Structure of the NF1 CLCL in RERF·LC·MS. 896 The structure of the CLCL was a tandem duplication between the junctions (indicated 897 by a vellow arrow and a blue arrow). The CLCL spanned 78 kb in the reference genome. (C) Structure of the SMARCA4 CLCL in PC-14. The structure of the CLCL was a 898 899 tandem duplication of the junctions (indicated by a yellow arrow and a blue arrow). The 900 CLCL spanned 50 kb in the reference genome. (D) Structure of the PTEN CLCL in PC-14. The structure of the CLCL was a combination of a local inversion and deletion. 901902We can trace the CLCL structure following the ordered arrows, and the junctions are indicated by colored arrows. The CLCL spanned 7 kb in the reference genome. (E) 903904Summary of mutation types of four-cancer-related genes in five cell lines. (\mathbf{F}) The 905number of CLCL junctions in each category of genomic contexts. 906

907 Figure 4 Aberrant transcriptional events caused by CLCL

908 (A) Structures of STK11 transcripts in RERF LC KJ. Sequencing tags of whole genome 909 sequencing (PromethION) and full-length RNA seq (MinION) were visualized by IGV. 910PC·14 RNA seq was also shown as a wild type control (B) Multi-layered statuses in the 911 STK11 region. Patterns of whole genome sequencing, ChIP-seq and RNA-seq tags of short read data were visualized by IGV. The status of RERF LC·KJ and PC·9 (control) is 912913 shown. (C) Structures of *PTEN* transcripts in PC-14. Sequencing tags of whole genome sequencing (PromethION) and full-length RNA-seq (MinION) were visualized by IGV. 914915The transcripts indicated that exon 6 was skipped (black arrow). (D) Expression levels 916 of STK11, NF1, SMARCA4 and PTEN in 26 lung cancer cell lines. Cell lines with 917 deleterious mutations, such as large deletions, frameshift indels and nonsense SNVs, 918 are shown in black. Cell lines with CLCLs are also shown in black with a diagonal line. 919 (E) Western blotting of genes affected by CLCLs and their downstream targets. MW: molecular weight. WT wild type. DEL large deletion. Bar charts indicate the 920 921normalized ratio of density of phosphorylated proteins and total proteins. Each protein 922is downstream of proteins encoded by CLCL genes.

923

924 Figure 5 CLCL as an overlooked cancerous aberration in cancers

925(A B) Detection of CLCLs in cell lines (A) and clinical samples (B) in short read data. 926The number of genes with CLCLs detected by short read data are shown in each 927category (TP: true positives, FN: false positives, FP: false positives; y-axis on the left 928side: also see **Supplementary Table S6**). The precision and recall rates are shown (y-axis 929 on the right side). The legend and color key are shown in the margin in A. (C) The 930 number of putative and expected CLCLs in whole exome sequencing data. TCGA-LUAD 931 and 97 Japanese lung adenocarcinoma datasets are shown in the left and right panels. (D) Putative CLCLs of cancer-related genes in 16 LUAD cases (shown as diamond). The 932933 driver mutation status of each case is shown at the bottom (blue and red). Gene types 934indicate driver genes that are significantly functionally altered in the indicated cancer 935 types.

936

937 TABLES

938 Table 1 General statistics of nanopore sequencing in LC2/ad

(Categories	MinION	PromethION		
Nur	nber of read	7,282,846	10,064,668		
N50 I	length of rea	ıds	30,606 bp	32,710 bp	
	Coverage		$31.0 \times$	$33.1 \times$	
Percentag	ge of mapped	l reads	$67.5 \ \%$	69.4 %	
Average len	gth of mapp	ed reads	16,452 bp	13,620 bp	
Average ider	ntity of map	ped reads	82.1 %	84.8 %	
	Number	tected in lung o			
Table 2 Summary of CLCLs detected in lung cancer cell lines					
Cell line	of		Genes		
	CLCLs				
LC2/ad	16	RPTOR, PTI	FABBR2, SART3, D PN13, RHEB, SPAC M8, PTPRD, EFNA.	G1, POLB*, FER1Le	
A549	1	RABGAP1L			
RERF·LC·KJ	7	COL11A1	L11A1, GTF2H1, LGALS3, STK11, CPT1C, IFNAR1, TWSG1		
RERF·LC·MS	7	LCK, HDAC1, CLEC2D, NF1, SLC8A2, MYT1 ACTB			
			5, PTEN, NAP1L1, INTS2, SMARCA4,), PRR5, SERPINB9, F13A1, AUTS2, TMEM38B		

943 *LC2/ad cells had two CLCL structures in the *POLB* gene.

944	Table 3 Clinical information and CLCL candidates of clinical samples
-----	--

945


Case	Age	Gender	Pathological stage	Histological characters	Driver mutations	Number of CLCLs	Genes with CLCLs
S1	76	Female	IA3	Large cell carcinoma	Not detected	0	-
S2	57	Female	IIB	Ad, micropapillary	EGFR L858R	2	CSMD3, SLC30A8
S3	54	Male	IIB	Ad, solid	NRAS Q61L	1	SNX25
S5	38	Male	IIIA	Ad, micropapillary	Not detected	0	-
S6	53	Female	IA3	Ad, papillary	EGFR exon 19 deletion	0	-
$\mathbf{S7}$	77	Female	IA3	Ad, micropapillary	EGFR exon 20 insertion	2	NLGN1, MEF2A
S8	85	Female	IB	Ad, papillary	EGFR exon 19 deletion	2	ASTN2, RNF20
S9	71	Female	IA1	Ad, lepidic	EGFR L858R	1	TSPAN8
S10	65	Female	IA3	Ad, papillary	EGFR L858R	3	AGBL4, ZFP82, ZNF681

946 Ad: Adenocarcinoma

947 SUPPLEMENTARY FIGURES AND TABLES

- 948 Supplementary Figure S1 General statistics of MinION and PromethION in four cell
- 949 **lines**
- 950 Supplementary Figure S2 IGV images of large deletions detected by MinION and
- 951 PromethION
- 952 Supplementary Figure S3 A novel genomic rearrangement in RERF-LC-KJ
- 953 Supplementary Figure S4 Pipeline for the detection of CLCLs
- 954 Supplementary Figure S5 An example CLCL from the clinical samples
- 955 Supplementary Figure S6 SV junctions detected by GenomonSV
- 956 Supplementary Figure S7 Representative histological images of clinical lung cancer
- 957 specimens
- 958 Supplementary Table S1 Summary of lung cancer cell lines
- 959 Supplementary Table S2 Sequencing statistics of MinION and PromethION
- 960 Supplementary Table S3 Candidate novel fusion genes
- 961 Supplementary Table S4 Histopathological information on lung cancer clinical samples
- 962 Supplementary Table S5 General statistics of PromethION in lung cancer clinical
 963 samples
- 964 Supplementary Table S6 Numbers of genes affected by CLCLs in cell lines and clinical
- 965 samples

Α



Dataset






Figure 2







STK11

PTEN in PC-14

